INT51180

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 1993
Last Reported 2006
Negated 1
Speculated 3
Reported most in Abstract
Documents 5
Total Number 8
Disease Relevance 2.16
Pain Relevance 4.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Nkx2-2) nucleus (Nkx2-2) molecular_function (Nkx2-2)
transcription factor binding (Nkx2-2)
Anatomy Link Frequency
plasma 1
visceral 1
spinal 1
paw 1
Nkx2-2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Calcitonin gene-related peptide 5 100.00 Very High Very High Very High
Hyperesthesia 4 100.00 Very High Very High Very High
Pain 4 100.00 Very High Very High Very High
nociceptor 3 100.00 Very High Very High Very High
anesthesia 2 100.00 Very High Very High Very High
antagonist 24 99.96 Very High Very High Very High
nud 3 98.40 Very High Very High Very High
substance P 6 98.20 Very High Very High Very High
withdrawal 3 98.08 Very High Very High Very High
Somatostatin 4 97.64 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pressure And Volume Under Development 3 99.36 Very High Very High Very High
Nociception 10 99.08 Very High Very High Very High
Dyspepsia 3 98.40 Very High Very High Very High
Hyperaesthesia 3 96.36 Very High Very High Very High
Injury 5 91.04 High High
INFLAMMATION 5 90.00 High High
Hyperalgesia 3 77.40 Quite High
Neuropathic Pain 4 75.00 Quite High
Pain 2 70.76 Quite High
Stress 1 51.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Effects of FK224, a novel cyclopeptide NK1 and NK2 antagonist, and CP-96,345, a nonpeptide NK1 antagonist, on development and maintenance of thermal hyperesthesia evoked by carrageenan injection in the rat paw.
Regulation (Effects) of NK2 in paw associated with hyperesthesia, antagonist and hyperaesthesia
1) Confidence 0.26 Published 1993 Journal Anesthesiology Section Title Doc Link 7694526 Disease Relevance 0.27 Pain Relevance 0.64
Use of non-peptide tachykinin receptor antagonists to substantiate the involvement of NK1 and NK2 receptors in a spinal nociceptive reflex in the rat.
Regulation (involvement) of NK2 in spinal associated with nociception, nociceptor and antagonist
2) Confidence 0.14 Published 1993 Journal Eur. J. Pharmacol. Section Title Doc Link 7682180 Disease Relevance 0.23 Pain Relevance 0.52
Role of tachykinin NK1 and NK2 receptors on colonic motility in anesthetized rats: effect of agonists.
Regulation (Role) of NK2 associated with anesthesia and agonist
3) Confidence 0.07 Published 1997 Journal Can. J. Physiol. Pharmacol. Section Title Doc Link 9276132 Disease Relevance 0 Pain Relevance 0.44
We examined the effects on both these phenomena of the selective NK1 and NK2 receptor antagonists, SR140333 and SR48968.
Spec (examined) Regulation (effects) of NK2 associated with antagonist
4) Confidence 0.07 Published 1998 Journal Fundam Clin Pharmacol Section Abstract Doc Link 9523190 Disease Relevance 0.23 Pain Relevance 0.18
The aim of the present study was to investigate the modulatory role of NK1 and NK2 antagonists on edema formation, and on hindpaw withdrawal latency to experimentally asses nociception.
Spec (investigate) Regulation (role) of NK2 associated with nociception, pressure and volume under development, antagonist and withdrawal
5) Confidence 0.05 Published 1999 Journal Burns Section Abstract Doc Link 10208386 Disease Relevance 0.77 Pain Relevance 0.45
Role of tachykinin NK1, NK2 and NK3 receptors in the modulation of visceral hypersensitivity in the rat.
Regulation (Role) of NK2 in visceral associated with nociceptor and nud
6) Confidence 0.04 Published 2003 Journal Neurosci. Lett. Section Title Doc Link 14583381 Disease Relevance 0.42 Pain Relevance 0.86
The cisplatin treatment significantly increased plasma somatostatin immunoreactivity and the expression of SSTR4 receptor detected both on the 11th and 22nd post-treatment days with no change in either CGRP, NK1, and NK2 receptor gene expression or plasma CGRP and substance P levels.
Neg (no) Regulation (change) of NK2 in plasma associated with somatostatin, substance p and calcitonin gene-related peptide
7) Confidence 0.03 Published 2006 Journal Neuropeptides Section Abstract Doc Link 16343617 Disease Relevance 0.19 Pain Relevance 0.68
The present study investigated the effects of the selective neurokinin-2 (NK2) receptor antagonist SR48968 in behavioral, electrophysiological, and biochemical tests sensitive to the action of prototypical antidepressants (fluoxetine, imipramine) or to corticotropin-releasing factor (CRF) receptor antagonists, which have been proposed recently as potential antidepressants.
Spec (investigated) Regulation (effects) of NK2 associated with antidepressant, antagonist and fluoxetine
8) Confidence 0.02 Published 2001 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11602654 Disease Relevance 0.05 Pain Relevance 0.38

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox